Table 2.

Summary table of the medications applied in the study population.

	Crohn's disease	Ulcerative colitis
Medication at inclusion, n [%]
Nothing	10 [17.9%]	6 [7.9%]
5-aminosalicylic acid	1 [1.79%]	27 [35.5%]
Corticosteroids	3 [5.36%]	13 [17.1%]
Azathioprine/6-mercaptopurine	10 [17.9%]	16 [21.1%]
Cyclosporine	1 [1.79%]	4 [5.3%]
Anti-TNF	16 [28.6%]	18 [23.7%]
Vedolizumab	13 [23.2%]	24 [31.6%]
Ustekinumab	10 [17.9%]	1 [1.3%]
Tofacitinib	0	5 [6.6%]
Medication after colonoscopy, n [%]
5-aminosalicylic acid	1 [1.79%]	24 [31.6%]
Corticosteroids	10 [17.9%]	10 [13.2%]
Azathioprine/6-mercaptopurine	4 [7.14%]	14 [18.4%]
Cyclosporine	0	2 [2.6%]
Anti-TNF	18 [32.1%]	20 [26.3%]
Vedolizumab	12 [21.4%]	21 [27.6%]
Ustekinumab	17 [30.4%]	1 [1.3%]
Tofacitinib	0	15 [19.7%]
Treatment change after colonoscopy, n [%]
New introduction of IM and/or biologic therapy	12 [21.4%]	16 [21.1%]
Continuation	25 [44.6%]	37 [48.7%]
Switch	9 [16.1%]	13 [17.1%]
Dose escalation	8 [14.3%]	7 [9.21%]

TNF, tumour necrosis factor; IM, immunomodulation.